Bristol-Myers Squibb (BMS) has announced that the European Commission has granted unconditional approval of BMS’ pending $74-billion acquisition of Celgene The companies had announced the deal in January 2019.

The transaction remains subject to additional customary closing conditions and other regulatory approvals, including in the US. BMS says it intends to close the Celgene transaction at the earliest possible date, which it currently expects to be by the end of 2019 or the beginning of 2020.

Source: Bristol-Myers Squibb